# Psoriasis Treatment Market

> Psoriasis Treatment Market Size, Growth Research Report By Treatment Type (Topical Treatments, Systemic Treatments, Phototherapy, Biologics), By Administration Route (Oral, Topical, Injectable, Intravenous), By Indication (Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis), By End User (Hospital, Dermatology Clinics, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Competitor Industry Analysis and Trends Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.2%
- **2025:** $ 28.6 Billion
- **2026:** $ 31.2 Billion
- **2035:** $ 68.8 Billion
- **Key Players:** Companies such as AbbVie (US), Amgen (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), GSK (GB), Eli Lilly (US), Sanofi (FR), UCB (BE) are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/2052-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** June 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769

---

## Market Summary

The Global Psoriasis Treatment Market size was valued at USD 28.6 Billion in 2025, and the market is projected to grow from USD 31.2 Billion in 2026 to USD 68.80 Billion by 2035, registering a CAGR of 9.2% during the forecast period 2026–2035. North America led the market in 2025 with over 45% share, generating around USD 12.87 Billion in revenue.
 
Rising global prevalence of psoriasis and other chronic inflammatory skin conditions is a major growth driver, supported by increasing awareness, improved diagnosis rates, and growing demand for advanced therapies, significantly accelerating adoption of effective and targeted psoriasis treatment solutions worldwide.
 
According to WHO, psoriasis affects approximately 2–3% of the global population, representing over 125 million people worldwide, while IHME reports skin diseases contribute to more than 42 million years lived with disability (YLDs) globally, highlighting strong and sustained demand for effective psoriasis treatment solutions.

## Market Drivers

### Growing Awareness and Education

The increasing awareness and education surrounding psoriasis are crucial drivers for the Psoriasis Treatment Market. Campaigns aimed at educating the public about the condition and its treatment options have led to a rise in diagnosis rates. Patients are now more informed about their treatment choices, which encourages them to seek medical advice.
 
This heightened awareness is particularly evident in regions where healthcare initiatives focus on chronic diseases. As more individuals understand the implications of psoriasis, the demand for effective treatments is expected to rise, thereby propelling the market forward.
 

- According to World Bank health indicators, global life expectancy has surpassed 73 years, increasing focus on chronic disease management and patient education. Growing healthcare awareness campaigns are encouraging earlier diagnosis of psoriasis, improving treatment-seeking behavior, and supporting wider adoption of advanced therapeutic options across both developed and emerging healthcare markets.

### Increasing Prevalence of Psoriasis

The rising incidence of psoriasis is a pivotal driver in the Psoriasis Treatment Market. Recent estimates indicate that approximately 2-3% of the population is affected by this chronic skin condition, leading to a growing demand for effective treatment options.
 
As awareness of psoriasis increases, more individuals seek medical intervention, thereby expanding the market. The prevalence of psoriasis is particularly notable in developed regions, where healthcare access is more readily available. This trend suggests that the market will continue to grow as healthcare providers develop new therapies to meet the needs of an expanding patient population.
 

- According to IHME data, skin and subcutaneous diseases collectively affect hundreds of millions of individuals globally each year. The substantial disease burden continues to drive demand for effective psoriasis management solutions, supporting investments in innovative therapies and expanding access to specialized dermatological care services worldwide.

### Advancements in Treatment Modalities

Innovations in treatment modalities are significantly influencing the Psoriasis Treatment Market. The introduction of biologic therapies, which target specific pathways in the immune system, has transformed the treatment landscape. These therapies have shown efficacy in moderate to severe cases, leading to increased adoption among healthcare professionals.
 
Furthermore, the market is witnessing a surge in topical treatments and systemic therapies, which cater to varying degrees of psoriasis severity. The continuous research and development efforts in this area indicate a promising future for the market, as new and improved therapies are likely to emerge.

### Regulatory Support for New Therapies

Regulatory support for the approval of new therapies is a vital driver in the Psoriasis Treatment Market. Regulatory agencies are increasingly expediting the review process for innovative treatments, particularly biologics and novel systemic therapies. This trend is encouraging pharmaceutical companies to invest in research and development, leading to a more diverse array of treatment options for patients.
 
The favorable regulatory environment not only accelerates the availability of new therapies but also enhances competition within the market. As a result, the market is likely to experience growth as new and effective treatments become accessible to patients.

### Rising Investment in Healthcare Infrastructure

The expansion of healthcare infrastructure is a significant factor impacting the Psoriasis Treatment Market. Increased investment in healthcare facilities and services enhances access to dermatological care, which is essential for effective psoriasis management.
 
Governments and private entities are focusing on improving healthcare systems, particularly in underserved areas. This investment is likely to facilitate better diagnosis and treatment options for psoriasis patients. As healthcare systems evolve, the market is poised to benefit from improved patient access and a broader range of treatment modalities.

## Future Outlook

The Psoriasis Treatment Market size is projected to reach USD 68.80 Billion by 2035, growing at a CAGR of 9.2%, driven by increasing prevalence, innovative therapies, and rising healthcare expenditure.

**New opportunities:**

- Development of personalized biologic therapies targeting specific patient profiles. Expansion of telehealth services for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) and consultations. Investment in digital health platforms for treatment adherence and education.

By 2035, the Psoriasis Treatment Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Topical Treatments (Largest) vs. Biologics (Fastest-Growing)

The Topical Treatments segment dominates the Psoriasis Treatment Market share at 48% due to its widespread use and accessibility for patients. This segment includes various therapies such as corticosteroids, vitamin D analogs, and retinoids, which are effective for mild to moderate cases of psoriasis. On the other hand, Biologics, which are advanced medications targeting specific parts of the immune system, are gaining traction and hold a significant part of the market due to their effectiveness in severe cases, resulting in their rapid growth.

Novartis continues investing heavily in dermatology innovation and patient-focused treatment solutions. The company's global pharmaceutical operations generated over USD 50 billion in annual revenue, highlighting strong industry commitment toward improving accessible treatment options, including topical therapies that remain the first-line approach for many psoriasis patients.

### By Administration Route: Topical (Largest) vs. Injectable (Fastest-Growing)

The administration route segment displays significant diversity, with topical treatments holding the largest Psoriasis Treatment Market share at 52%. These treatments are favored due to their direct application on affected areas, resulting in minimal systemic exposure. Injectables, while representing a smaller share currently, are emerging as a potent contender due to their efficacy and the increasing patient and physician acceptance. Oral and intravenous routes, though available, occupy more specialized niches within the market.

Bristol Myers Squibb maintains substantial investment in immunology and inflammatory disease research. With annual R&D spending exceeding USD 9 billion, the company supports development of innovative treatment approaches that complement widespread topical therapy usage, reinforcing the importance of convenient administration routes in psoriasis management.

### By Indication: Plaque Psoriasis (Largest) vs. Guttate Psoriasis (Fastest-Growing)

The psoriasis treatment market features a diverse range of indications, with Plaque Psoriasis accounting for the largest market share at 62%. This subtype is the most prevalent form of psoriasis and is characterized by raised, inflamed lesions covered with silvery scales. Guttate Psoriasis, while smaller in share compared to Plaque, has been noted for its rapid growth, primarily in younger populations and influenced by factors such as streptococcal infections. As the awareness and diagnosis of various psoriasis types improve, the market distribution reflects these changes in patient demographics and symptom presentations.

GSK continues expanding its immunology research programs focused on chronic inflammatory diseases. Plaque psoriasis remains the most commonly diagnosed form globally, and ongoing investments in targeted therapies and precision medicine initiatives are improving treatment effectiveness and strengthening clinical management across large patient populations.

### By End User: Hospital (Largest) vs. Dermatology Clinics (Fastest-Growing)

Hospitals account for the largest share in the psoriasis treatment market, representing 46% of the end-user segment. This is primarily due to their capacity to offer comprehensive care, advanced treatment options, and the availability of specialist healthcare professionals. Dermatology clinics follow closely, yet they are witnessing an impressive surge in demand as more patients seek specialized care in a focused environment. Homecare settings are becoming increasingly relevant, particularly for those preferring convenience and personalized treatment regimens, although they hold a smaller share compared to hospitals and clinics.

Sanofi invests significantly in specialty care and immunology innovation, supporting hospital-based treatment ecosystems. With annual pharmaceutical sales exceeding EUR 40 billion, the company contributes to expanding access to advanced psoriasis therapies delivered through hospitals, where multidisciplinary expertise and comprehensive care services remain critical.

## Regional Market Share Analysis

### North America : Leading Market for Treatments

North America leads in the Psoriasis Treatment Market size, accounting for over 45% of the global revenue in 2025. The region's growth is driven by increasing prevalence of psoriasis, advancements in treatment options, and supportive regulatory frameworks. The U.S. Food and Drug Administration (FDA) has accelerated the approval process for innovative therapies, enhancing market dynamics.

- According to CDC data, approximately 6 in 10 U.S. adults have at least one chronic disease, increasing demand for long-term disease management solutions. This growing healthcare burden supports adoption of innovative psoriasis treatments and strengthens North America's position as the leading regional market for advanced dermatological therapies.

The demand for biologics and targeted therapies is on the rise, further propelling market growth. The competitive landscape in North America is robust, with key players such as AbbVie, Amgen, and Johnson & Johnson leading the market. The presence of advanced healthcare infrastructure and high healthcare expenditure supports the adoption of new therapies. Additionally, ongoing clinical trials and research initiatives are expected to introduce novel treatment options, solidifying North America's position as a leader in the market.

- Eli Lilly and Company reported annual revenue exceeding USD 45 billion, supported by continued investment in immunology and biologic therapies. Ongoing clinical advancements and strong research funding are accelerating treatment innovation, reinforcing North America's leadership in psoriasis therapy development and commercialization.

### Europe : Emerging Market with Growth Potential

Europe Psoriasis Treatment Market size was valued at USD 8.58 billion in 2025, making it the second-largest regional market with a 30% share. The region is witnessing significant growth due to rising awareness about psoriasis, increasing healthcare investments, and favorable reimbursement policies. The European Medicines Agency (EMA) has been proactive in approving new therapies, which has stimulated market demand.

- The European Medicines Agency oversees medicines for approximately 450 million people across the European Union. Continued approvals of innovative biologics and immunology treatments, combined with supportive reimbursement frameworks, are improving patient access to advanced psoriasis therapies and supporting sustained market growth throughout Europe.

The growing focus on personalized medicine is also a key driver of market expansion in Europe. Leading countries in Europe include Germany, France, and the UK, which are home to several prominent pharmaceutical companies. Key players such as Novartis, GSK, and Sanofi are actively involved in developing innovative treatments. The competitive landscape is characterized by a mix of established companies and emerging biotech firms, fostering a dynamic environment for psoriasis treatment advancements.

### Asia-Pacific : Rapidly Growing Treatment Sector

The Asia-Pacific region is emerging as a significant player in the psoriasis treatment market, accounting for approximately 20% of the global market share. The growth is driven by increasing awareness of skin diseases, rising disposable incomes, and expanding healthcare access. Countries like China and India are witnessing a surge in demand for psoriasis treatments, supported by government initiatives aimed at improving healthcare infrastructure and access to medications.

Regulatory bodies are also streamlining approval processes for new therapies, enhancing market dynamics. In the competitive landscape, key players such as Eli Lilly and Pfizer are making substantial investments in the region. The presence of local pharmaceutical companies is also increasing, contributing to a diverse market. The growing trend of telemedicine and digital health solutions is expected to further boost treatment accessibility and patient engagement in the Asia-Pacific region, driving future growth.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region is gradually developing its psoriasis treatment market, holding approximately 5% of the global market share. The growth is hindered by challenges such as limited healthcare infrastructure, high treatment costs, and varying levels of awareness about psoriasis. However, increasing investments in healthcare and initiatives to improve access to treatments are expected to drive market growth in the coming years. Regulatory bodies are working to enhance the approval processes for new therapies, which could stimulate market dynamics.

Leading countries in the MEA region include South Africa and the UAE, where there is a growing presence of international pharmaceutical companies. Key players are beginning to explore opportunities in this region, focusing on affordable treatment options. The competitive landscape is evolving, with local firms collaborating with global companies to enhance treatment availability and awareness, paving the way for future growth in the market.

## Competitive Benchmarking

The Psoriasis Treatment Market is characterized by a dynamic competitive landscape, driven by a confluence of innovation, strategic partnerships, and a growing emphasis on personalized medicine. Major players such as AbbVie (US), Amgen (US), and Novartis (CH) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their product offerings.
 
AbbVie (US) continues to focus on its flagship product, Humira, while also investing in the development of new therapies that target specific patient populations. Meanwhile, Amgen (US) is expanding its portfolio through strategic collaborations aimed at enhancing its biologics pipeline, which is crucial in addressing the diverse needs of psoriasis patients. Novartis (CH) is similarly positioned, emphasizing its commitment to innovation through the development of novel therapies that not only improve efficacy but also reduce treatment burden for patients.
 
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the psoriasis treatment market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of treatment options, catering to different patient demographics and preferences, while also fostering a competitive environment that encourages continuous innovation. 
 
In August 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of oral therapies for psoriasis. This collaboration is expected to accelerate the development timeline and enhance AbbVie’s competitive edge in the oral treatment segment, which is gaining traction among patients seeking alternatives to injectable therapies. The strategic importance of this partnership lies in its potential to broaden AbbVie’s market share and reinforce its position as a leader in psoriasis treatment. 
 
In September 2025, Amgen (US) launched a new digital health platform aimed at improving patient engagement and adherence to psoriasis treatments. This initiative reflects a growing trend towards digitalization in healthcare, where technology is leveraged to enhance patient outcomes. By integrating digital tools into its treatment protocols, Amgen (US) not only improves patient experience but also gathers valuable data that can inform future product development.
 
 In October 2025, Novartis (CH) unveiled a sustainability initiative focused on reducing the environmental impact of its manufacturing processes for psoriasis treatments. This move aligns with the increasing demand for sustainable practices within the pharmaceutical industry and positions Novartis as a forward-thinking player committed to corporate social responsibility. The strategic importance of this initiative is multifaceted, as it not only addresses regulatory pressures but also resonates with environmentally conscious consumers.
 
As of October 2025, the competitive trends in the psoriasis treatment market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability, ultimately enhancing patient care and treatment outcomes.

## Recent News & Developments

In recent months, the Global Psoriasis Treatment Market has experienced significant developments, particularly with companies like AbbVie making strides in Research and Development for improved biologic therapies. In September 2023, Pfizer launched a new clinical trial aimed at exploring innovative treatments for moderate to severe psoriasis, showcasing ongoing commitment in this sector. Similarly, in August 2023, Merck announced advancements in their psoriasis portfolio, aimed at enhancing patient outcomes. 

Major companies including Johnson and Johnson and Novartis continue to engage in improving treatment options, while GSK has been actively investing in research to tap into emerging treatment modalities. In terms of mergers and acquisitions, in July 2023, AstraZeneca completed the acquisition of a portfolio from a small biotech company focused on skin diseases, significantly enhancing their capabilities in the psoriasis market. 

Reports indicate that there is growing momentum for biologic therapies, which has led to increased valuations for key players in the market. Over the past two to three years, the industry has witnessed a marked increase in interest and investment, particularly in targeting more effective treatment options for patients, as the demand for innovative solutions continues to rise globally.

## Report Scope

| MARKET SIZE 2025 | 28.6(USD Billion) |
| --- | --- |
| MARKET SIZE 2026 | 31.2(USD Billion) |
| MARKET SIZE 2035 | 68.8(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.2% (2026 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2025 |
| Market Forecast Period | 2026 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AbbVie (US), Amgen (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), GSK (GB), Eli Lilly (US), Sanofi (FR), UCB (BE) |
| Segments Covered | Treatment Type, Administration Route, Indication, End User, Regional |
| Key Market Opportunities | Emergence of biologics and personalized therapies enhances treatment options in the market. |
| Key Market Dynamics | Rising demand for biologics drives innovation and competition in the psoriasis treatment landscape. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Psoriasis Treatment Market as of 2024?**
A: The Psoriasis Treatment Market was valued at 7.45 USD Billion in 2024.

**Q: What is the projected market size for the Psoriasis Treatment Market by 2035?**
A: The market is projected to reach 12.0 USD Billion by 2035.

**Q: What is the expected CAGR for the market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during 2025 - 2035 is 4.43%.

**Q: Which segment of the Psoriasis Treatment Market had the highest valuation in 2024?**
A: In 2024, the Biologics segment had the highest valuation at 2.95 USD Billion.

**Q: What are the projected values for Topical Treatments in the Psoriasis Treatment Market by 2035?**
A: Topical Treatments are projected to reach 2.5 USD Billion by 2035.

**Q: How does the market for Injectable treatments compare to Oral treatments in 2024?**
A: In 2024, the market for Injectable treatments was valued at 2.0 USD Billion, while Oral treatments were also at 1.5 USD Billion.

**Q: What is the expected growth for the Homecare Settings segment by 2035?**
A: The Homecare Settings segment is expected to grow to 5.0 USD Billion by 2035.

**Q: Which key players are leading the Psoriasis Treatment Market?**
A: Key players in the market include AbbVie, Amgen, Johnson & Johnson, and Novartis.

**Q: What is the projected value of Plaque Psoriasis treatments by 2035?**
A: Plaque Psoriasis treatments are projected to reach 5.0 USD Billion by 2035.

**Q: What is the anticipated market performance for Dermatology Clinics in the coming years?**
A: Dermatology Clinics are expected to grow to 3.0 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769*